Denali Therapeutics Inc. — Director's Dealing 2021

Mar 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-03-01

Reporting Person: Ho Carole (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-01	Common Stock	S	1327	$64.541	Disposed	170906	Indirect
2021-03-01	Common Stock	S	2871	$65.735	Disposed	168035	Indirect
2021-03-01	Common Stock	S	1173	$67.067	Disposed	166862	Indirect
2021-03-01	Common Stock	S	1320	$68.009	Disposed	165542	Indirect
2021-03-01	Common Stock	S	208	$68.865	Disposed	165334	Indirect
2021-03-01	Common Stock	S	125	$70.065	Disposed	165209	Indirect
2021-03-01	Common Stock	S	68	$71.27	Disposed	165141	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	25000	Indirect
Common Stock	82382	Direct

Footnotes

F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.

F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $64.20 to $65.155 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.

F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $65.26 to $66.21 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F5: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $66.375 to $67.35 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F6: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $67.45 to $68.335 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F7: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $70.03 to $70.32 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F8: The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust, for which the Reporting Person serves as trustee.

F9: Includes 80,906 restricted stock units.